Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Pilot Study of KPL-914 in Recurrent Pericarditis

Next Previous
Trial Profile

An Open-Label Pilot Study of KPL-914 in Recurrent Pericarditis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilonacept (Primary)
  • Indications Pericarditis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Kiniksa Pharmaceuticals

    • Most Recent Events

    • 20 Nov 2019 According to a Kiniksa Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for rilonacept for the treatment of recurrent pericarditis, based on the data from this study.
    • 18 Nov 2019 Results presented at the American Heart Association Scientific Sessions 2019
    • 16 Nov 2019 Results presented in a Kiniksa Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top